Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AtaiBeckley Inc (ATAI : NSDQ)

• Company Description    AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing mental health treatments. The company's pipeline of novel therapies includes BPL-003 for treatment-resistant depression, VLS-01 for TRD and EMP-01 for social anxiety disorder. AtaiBeckley Inc., formerly known as Atai Beckley N.V., is based in NEW YORK. Number of Employees: 54

• Price / Volume Information    Yesterday's Closing Price: $7.39 Daily Weekly Monthly 20 Day Moving Average: 6,961,726 shares Shares Outstanding: 370.86 (millions) Market Capitalization: $2,740.69 (millions) Beta: 1.54 52 Week High: $7.45 52 Week Low: $3.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.93% 2.39% 12 Week 92.45% 88.35% Year To Date 80.68% 60.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL PROF. J.H. BAVINCKLAAN 7 - AMSTELVEEN, P 1183 NLD ph: 49-89-2153-9035 fax: - ir@ataibeckley.com http://www.ataibeckley.com

• General Corporate Information    Officers Srinivas Rao - Chief Executive Officer Christian Angermayer - Chairman Anne Johnson - Chief Financial Officer Sabrina Martucci Johnson - Director Amir Kalali - Director Peer Information AtaiBeckley Inc (CORR.) AtaiBeckley Inc (RSPI) AtaiBeckley Inc (CGXP) AtaiBeckley Inc (BGEN) AtaiBeckley Inc (GTBP) AtaiBeckley Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04650F101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 370.86 Most Recent Split Date: (:1) Beta: 1.54 Market Capitalization: $2,740.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 11.11 Price/Cash Flow: - Price / Sales: 612.72 EPS Growth vs. Year Ago Period: 35.71% vs. Previous Quarter: -12.50% Sales Growth vs. Year Ago Period: 137.00% vs. Previous Quarter: 78.62% ROE 06/30/26 - -88.30 03/31/26 - -89.79 12/31/25 - -87.51 ROA 06/30/26 - -58.88 03/31/26 - -63.58 12/31/25 - -63.88 Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Operating Margin 06/30/26 - -3,156.56 03/31/26 - -3,910.49 12/31/25 - -3,253.78 Net Margin 06/30/26 - -14,938.36 03/31/26 - -19,019.44 12/31/25 - -16,142.01 Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©